Roche's Columvi (Glofitamab) Regimen Receives the EC’s Approval to Treat R/R Diffuse Large B-Cell Lymphoma (DLBCL)
Shots:
- The EC has granted full approval to Columvi + GemOx for ASCT-ineligible r/r DLBCL pts based on P-III (STARGLO) trial assessing the regimen vs MabThera/Rituxan + GemOx in previously treated DLBCL pts
- At 11.3mos. mFU (primary analysis), trial showed improved OS, a 41% reduction in death risk, with a 63% improvement in PFS. At 20.7mos. mFU (follow-up analyses), mOS was 25.5 vs 12.9mos. & CRs were seen in 58.5% vs 25.3% pts
- Columvi is also being evaluated in P-III (SKYGLO) trial in combination with Polivy + MabThera/Rituxan, cyclophosphamide, doxorubicin & prednisone (Pola-R-CHP) vs Pola-R-CHP in previously untreated DLBCL pts
Ref: Globenewswire | Image: Roche
Related News:- Oxford BioTherapeutics and Roche Collaborate to Discover Next-Gen Biologics for Cancer Treatment
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
